Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 10/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 10/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 1.00 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.79 |
| ▸ | CDC37 | Q16543 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963758 | 0.90 | HSP90AA1 (1.00) | HSP90AB1ERBB2HSP90AA1HSP90B1 | |
| SCHEMBL5150302 | 0.90 | ERBB2 (0.81) | HSP90AB1ERBB2HSP90AA1HSP90B1CDC37 | |
| SCHEMBL5039130 | 0.90 | ERBB2 (0.81) | HSP90AB1ERBB2HSP90AA1HSP90B1CDC37 | |
| SCHEMBL1963694 | 0.90 | ERBB2 (0.81) | HSP90AB1ERBB2HSP90AA1HSP90B1CDC37 | |
| SCHEMBL5039362 | 0.89 | ERBB2 (0.80) | HSP90AB1ERBB2HSP90AA1HSP90B1CDC37 | |
| SCHEMBL5132864 | 0.89 | ERBB2 (0.80) | HSP90AB1ERBB2HSP90AA1HSP90B1CDC37 | |
| SCHEMBL5035349 | 0.89 | ERBB2 (0.80) | HSP90AB1ERBB2HSP90AA1HSP90B1CDC37 | |
| SCHEMBL5039997 | 0.89 | HSP90AB1 (0.79) | HSP90AB1ERBB2HSP90AA1HSP90B1CDC37 | |
| SCHEMBL5038267 | 0.88 | ERBB2 (0.83) | HSP90AB1ERBB2HSP90AA1HSP90B1CDC37 | |
| SCHEMBL17900411 | 0.88 | HSP90B1 (1.00) | HSP90AB1ERBB2HSP90AA1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4397691-B2 | — | — | 2010-01-13 | — | — | JP | claimed |
| JP-2005511565-A | — | — | 2005-04-28 | — | — | JP | claimed |
| EP-1440072-A4 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | CONFORMA THERAPEUTIC CORP (US) | 2005-02-02 | — | — | EP | claimed |
| EP-1440072-A2 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | Conforma Therapeutic Corporation (US) | 2004-07-28 | — | — | EP | claimed |
| WO-2003037860-A2 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | CONFORMA THERAPEUTICS CORPORATION (US) | 2003-05-08 | — | — | WO | claimed |
| EP-2136799-B1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | UNIV STRASBOURG (FR) | 2017-10-04 | — | — | EP | disclosed |
| EP-2254880-B1 | Macrocyclic prodrug compounds useful as therapeutics | NEXGENIX PHARMACEUTICALS (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20140135290-A1 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | ONCOSYNERGY, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20110237560-A1 | MODULATING AND/OR DETECTING ACTIVATION INDUCED DEAMINASE AND METHODS OF USE THEREOF | ADAERATA, LIMITED PARTNERSHIP (CA) | 2011-09-29 | — | — | US | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20050049263-A1 | Purine analogs having hsp90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-03-03 | — | — | US | disclosed |
| EP-1440072-A4 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | CONFORMA THERAPEUTIC CORP (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1440072-A2 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | Conforma Therapeutic Corporation (US) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037860-A2 | PURINE ANALOGS HAVING HSP90-INHIBITING ACTIVITY | CONFORMA THERAPEUTICS CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885ERBB2 915/4885HSP90AA1 2/4885 |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885ERBB2 1609/4885HSP90AA1 2/4885 |
| US-20050049263-A1 | Purine analogs having hsp90-inhibiting activity | HSP90B1, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885ERBB2 3334/4885HSP90AA1 3/4885 |
| US-20140135290-A1 | MACROCYCLIC PRODRUG COMPOUNDS USEFUL AS THERAPEUTICS | ADCYAP1R1, CYP19A1, THOP1 | HSP90AB1 3953/4885ERBB2 982/4885HSP90AA1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.